跳至主要内容
临床试验/NCT01652326
NCT01652326已完成不适用

Clinical Quality Improvement of Benzodiazepine-Resistant Alcohol Withdrawal Syndrome

University of Pittsburgh1 个研究点 分布在 1 个国家目标入组 792 人开始时间: 2012年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
792
试验地点
1
主要终点
Identify those risk factors predictive of benzodiazepine-resistant alcohol withdrawal syndrome

研究概览

简要总结

The overarching goal of this project is to improve the clinical quality of patients with Benzodiazepine-resistant alcohol withdrawal syndrome.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • a requirement of either 200 mg of diazepam (or diazepam equivalents) in 4 hrs;
  • > 40mg of diazepam (or diazepam equivalents) in 1 hr; or
  • an individual dose of 40 mg or greater of intravenous diazepam for control of agitation

排除标准

  • if < 18 years of age or had evidence of use of other illicit substances as determined by urine toxicology screen

研究组 & 干预措施

Benzodiazepine-resistant

those patients with either 1) a requirement of either 200 mg of diazepam (or diazepam equivalents) in 4 hrs; 2) >40mg of diazepam (or diazepam equivalents) in 1 hr; or 3) an individual dose of 40 mg or greater of intravenous diazepam for control of agitation

干预措施: Diazepam (Drug)

结局指标

主要结局

Identify those risk factors predictive of benzodiazepine-resistant alcohol withdrawal syndrome

时间窗: up to 38 months

次要结局

  • Drug utilization of phenobarbital, propofol, dexmedetomidine, and ketamine in benzodiazepine-resistant alcohol withdrawal syndrome(Up to 38 months)
  • Effectiveness of phenobarbital, propofol, dexmedetomidine, and ketamine in benzodiazepine-resistant alcohol withdrawal(Up to 38 months)
  • Tolerability of phenobarbital, propofol, dexmedetomidine, and ketamine in benzodiazepine-resistant alcohol withdrawal(Up to 38 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验